Receptor tyrosine kinase (RTK) inhibitors have been approved for the treatment of NTRK fusion (NTRK+) and RET fusion (RET+) positive solid tumors in a tumor‐agnostic manner. This evidence concerns the gene NTRK1 and neoplasm.